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Abstract
This study investigated the accuracy, drift, and clinical usefulness of a new optical transcutaneous oxygen tension (tcPO2)
measuring technique, combined with a conventional electrochemical transcutaneous carbon dioxide (tcPCO2) measurement
and reflectance pulse oximetry in the novel transcutaneous OxiVenT™ Sensor. In vitro gas studies were performed to measure
accuracy and drift of tcPO2 and tcPCO2. Clinical usefulness for tcPO2 and tcPCO2 monitoring was assessed in neonates. In
healthy adult volunteers, measured oxygen saturation values (SpO2) were compared with arterially sampled oxygen saturation
values (SaO2) during controlled hypoxemia. In vitro correlation and agreement with gas mixtures of tcPO2 (r = 0.999, bias
3.0 mmHg, limits of agreement − 6.6 to 4.9 mmHg) and tcPCO2 (r = 0.999, bias 0.8 mmHg, limits of agreement − 0.7 to 2.2 mm
Hg) were excellent. In vitro drift was negligible for tcPO2 (0.30 (0.63 SD)mmHg/24 h) and highly acceptable for tcPCO2 (− 2.53
(1.04 SD) mm Hg/12 h). Clinical use in neonates showed good usability and feasibility. SpO2-SaO2 correlation (r = 0.979) and
agreement (bias 0.13%, limits of agreement − 3.95 to 4.21%) in healthy adult volunteers were excellent. The investigated
combined tcPO2, tcPCO2, and SpO2 sensor with a new oxygen fluorescence quenching technique is clinically usable and
provides good overall accuracy and negligible tcPO2 drift. Accurate and low-drift tcPO2 monitoring offers improved measure-
ment validity for long-term monitoring of blood and tissue oxygenation.
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1 Introduction
Transcutaneous blood gas monitoring is based on the diffu-
sion of oxygen (O2) and carbon dioxide (CO2) from the blood
to the skin surface [1]. Transcutaneous blood gas sensors lo-
cally heat the skin to induce vasodilation, resulting in an in-
crease in supplied O2 and clearance of CO2 [2, 3]. The diffu-
sion capacity of the skin is however markedly lower for O2
than for CO2 [4], additionally influenced by the thickness [5,
6] and microcirculatory condition [7] of the skin. As a conse-
quence the measurement of transcutaneous oxygen (tcPO2)
[8] requires relatively high sensor temperatures of 43 to 44
°C [9] for tcPO2 to correlate with arterial oxygen tension
(PaO2), which due to skin thickness only results in tcPO2
values approaching PaO2 in infants and young children
[10–12].
Conventional transcutaneous blood gas sensors are based
on the electrochemical techniques introduced by Clark [13]
for tcPO2 and Stow-Severinghaus [14] for tcPCO2. For
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decades the Clark-type electrode has been the only clinically
available technique for tcPO2 measurements [15]. It measures
oxygen by reduction, lowering the actual and thereby mea-
sured oxygen level in the superficial skin [16, 17].
Additionally there is measurement drift over time with both
techniques [18], hindering usability due to reduced accuracy,
frequent calibrations and membrane changes. These limita-
tions in reliability and usability of tcPO2 measurements [19]
have held back a widespread clinical use similar to that of
tcPCO2 measurements. However, tcPO2 offers advantages
over SpO2 in infants in which blood gas sampling is indicated
for the measurement of PaO2, precise PaO2 targeting is re-
quired or the oxygen dissociation curve is markedly shifted
[20, 21]. In adults the use of tcPO2 is limited to oxygen trend
monitoring due to an insuperable underestimation of PaO2
[22]. In addition measurement drift hinders clinical usability.
Removing measurement drift as an influence on the measure-
ment by implementing drift-free optical techniques could
therefore significantly improve usability of tcPO2 measure-
ments [23]. The recently introduced OxiVenT™ Sensor
(SenTec AG, Therwil, Switzerland) combines reflectance
pulse oximetry and a conventional electrochemical Stow-
Severinghaus-type tcPCO2 measurement with an optical oxy-
gen sensing technique for measuring tcPO2. Fluorescence
quenching [24] is the optical technique used for the measure-
ment of oxygen, making it potentially free of drift. The main
challenge in the development of this sensor was to combine
two optical techniques, fluorescence quenching and pulse ox-
imetry, without mutual interference into a single sensor which
also contains an electrochemical Stow-Severinghaus tcPCO2
measurement. In this article we will discuss the technical as-
pects of implementing fluorescence quenching in a combined
sensor, provide the first results on measurement accuracy and
evaluate its clinical implications.
2 Methods
2.1 A novel combined transcutaneous sensor
The OxiVenT™ Sensor is the first transcutaneous sensor in
which an optical tcPO2 measurement is combined with an
electrochemical Stow-Severinghaus-type tcPCO2 measure-
ment and reflective pulse oximetry (Fig. 1). The sensor weighs
2.7 g and has a diameter of 14 mm and a height of 9 mm. All
measurements are digitized within the sensor and
preprocessed. The principle of an electrolyte-filled diffusion
chamber is retained for the tcPCO2 measurement. For measur-
ing oxygen, the sensor contains an oxygen fluorescence
quenching dye surface which is back-lit by an excitation
light-emitting diode. On the same side of the dye, the excita-
tion light is measured with a wavelength-filtered photodetec-
tor. In order to provide parallel optical measurements of tcPO2
and SpO2, the respective light sources emit in an alternating
intermittent fashion. The sensor contains dual temperature
sensing for accurate heating control. The sensor can be at-
tached to the skin using either an ear clip or adhesive rings,
minimizing pressure on the skin.
2.2 Measuring principles and technology
2.2.1 TcPO2 measurement and fluorescence quenching
The OxiVenT™ Sensor measures oxygen levels with an opti-
cal technique called oxygen fluorescence quenching [24].
This technique relies on the excitation of a dye molecule by
the absorption of a photon emitted by a light-emitting diode
with a peak wavelength of approximately 500 nm, moving the
molecule to a higher energy state. Without the presence of an
oxygen molecule, the dye molecule will emit a photon at a
lower specific emission wavelength (approximately 650 nm)
and return to its base energy state. In the presence of an oxy-
gen molecule, the oxygen will quench the dye and thereby
prevent photon emission. In the sensing dye surface of the
OxiVenT™ Sensor, fluorescence emission of each dye mole-
cule occurs non-synchronously during a certain time interval.
This results in a fluorescence intensity and decay time interval
that relates to the amount of oxygen that quenches dye fluo-
rescence. Selectively and intermittently the light intensity at
the 650-nm band is measured, out of which the decay curve is
reconstructed and the measured oxygen values are inferred.
The oxygen diffusion to the dye results in a typical 90% re-
sponse time of under 150 s. Contrary to a Clark-type electrode
which reduces oxygen, influencing the oxygen level measure-
ment itself, the fluorescence quenching technique does not
affect oxygen levels.
2.2.2 TcPCO2 measurement
In the OxiVenT™ Sensor, CO2 is measured with a Stow-
Severinghaus-type electrode. This technique is used in the
majority of currently commercially available transcutaneous
sensors and consists of a pH electrode in an electrolyte buffer
containing sodium bicarbonate, covered by a gas-permeable
membrane. Carbon dioxide diffuses from the skin through the
membrane, where it causes a carbonic acid dissociation reac-
tion. This in turn changes the pH of the solution, which is
detected by the pH electrode and causes a potential change
between the pH electrode and the reference silver/silver chlo-
ride electrode. In sensors with an electrochemical tcPO2
(Clark-type) and tcPCO2 measurement the Clark-type elec-
trode and its inherent oxygen consumption influence pHwith-
in the diffusion chamber. Without this influence on the
tcPCO2 measurement, there is potentially a reduction in mea-
surement drift. Multiple patient factors and sensor temperature
influence the speed at which CO2 diffuses from the skin, and
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thereby the delay in measuring the changes in arterial values
transcutaneously. In practice, this delay is usually 20–80 s
from changes in ventilation to their effect on transcutaneous
measurements [25, 26].
2.2.3 Reflective two-wavelength pulse oximetry
In pulse oximetry, the optically measured ratio between
oxygenated and deoxygenated hemoglobin is used to
measure oxygen saturation. By sending two light frequen-
cies (660-nm and 880–890-nm wavelengths) through tis-
sue, the light intensity that results after absorption of light
by the two forms of hemoglobin can be used to calculate a
ratio between the two. Only the pulsatile part of the signal
is analyzed as it ideally represents the arterial component
of the signal. Using a calibration model, based on mea-
surements in healthy volunteers, for each ratio, this results
in a specific oxygen saturation. Although a shift in the
oxygen dissociation curve can influence the interpretation
of SpO2 values in relation to the actual PaO2, this tech-
nique is one of the most used oxygen monitoring tech-
niques. Two variants of the technique are often used;
transmission and reflectance pulse oximetry. In transmis-
sion pulse oximetry the light emitter and detector are
placed opposite to each other on both sides of tissue
(e.g. a finger), while in reflectance pulse oximetry the
emitter and detector are placed next to each other. This
means that in transmission pulse oximetry the light path is
linear and a relatively large part of the emitted light
reaches the detector. In reflectance pulse oximetry the
detected light is the part that is scattered and reflected
back from the tissue, resulting in a weaker signal when
compared with transmission pulse oximetry. In transcuta-
neous sensors the arterialization caused by locally heating
the skin markedly improves the reflective signal-to-noise
ratio [27].
2.3 Sensor validation methods
2.3.1 Hardware and software
All studies were performed using OxiVenT™ sensors with
software versions 01.09-01.58, connected to a SenTec
Digital Monitor (SDM) with software versions 08.00.0-
08.01.1 (SenTec Monitoring Board) and 06.00.01-06.01.00
(Multi Parameter Board).
2.3.2 In vitro gas studies for the validation of tcPO2
and tcPCO2
An in vitro validation of the transcutaneous (O2 and CO2)
measurements of the OxiVenT™ Sensor was performed with
10 sensors for each parameter in order to determine the accu-
racy and drift of these measurements. Prior to the protocol, the
sensors were allowed to stabilize. Testing methods were in
concordance with the FDA Guidance on cutaneous carbon
dioxide and oxygen monitors (clause 6.2), as well as IEC
60601-2-23 [28]. Accuracy was tested by cycling through
different combinations of gas concentrations of O2 and CO2.
Each gas mixture was allowed to stabilize for 10 min, after
which a data point was collected for each step. In the tcPCO2
accuracy test, a total of 4 data points for both 3% CO2 and 5%
CO2 as well as 8 data points for 10% CO2 were collected.
After 4 cycles, an additional measurement of nitrogen with
0% CO2 was performed. A comparable method was used for
the tcPO2 accuracy test. This results in 4 data points for both
2%O2 and 10% O2 as well as 8 data points for 20% O2 after 4
cycles. Following these 4 cycles, additional measurements
with nitrogen (0% O2) and with 100% O2 were performed.
For the drift test, the sensors were exposed to humidified test
gas (20% O2/10% CO2) for the duration of the calibration
interval (24 h for tcPO2 and 12 h for tcPCO2). The total drift
over the calibration interval is given as a percentage of the
d
a c b
e
Fig. 1 Inside view of the fully
digital OxiVenT™ Sensor,
showing (a) tcPO2 optical
module, (b) tcPCO2
electrochemical module, (c) pulse
oximetry light-emitting diode, (d)
pulse oximetry photodiode, and
(e) flexible circuit board
containing the temperature
sensors and all electronic
components and microprocessor
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initial reading. In addition, the drift is given as %/h for the first
hour (0–1 h) and last hour (11–12 h/23–24 h) of the calibration
interval.
2.3.3 Clinical use of tcPO2 and tcPCO2
At the Neonatal Intensive Care Unit at Erasmus MC – Sophia
Children’s Hospital (Rotterdam, the Netherlands), transcuta-
neous blood gas monitoring in preterm (24–32 weeks GA)
and term neonates is performed as standard care. Existing,
local, age-specific protocols for sensor temperatures and site
times were applied for extreme preterm neonates (< 26 weeks
GA: 42 °C, 2 h) and less preterm and term neonates (≥ 26
week GA: 43 °C, 3 h). TcPCO2 was calibrated initially, and
when the site time elapsed, tcPO2 was calibrated initially and
daily for verification during a tcPCO2 calibration. Several
clinical examples were selected to demonstrate the usability
and feasibility of transcutaneous blood gas monitoring of
tcPO2 and tcPCO2 with the OxiVenT™ Sensor during various
clinical events. SpO2 measurements (Masimo SET®,
Masimo, Irvine, CA, USA) were recorded simultaneously
with averaging over 12 s.
2.3.4 Validation of SpO2 in healthy volunteers
Validation of the OxiVent™ Sensor SpO2 measurements was
performed with a clinical study in healthy volunteers at the
University of California (San Francisco, USA). Approval
from the institutional IRB was obtained for the study protocol.
The study was carried out according to the FDA Guidance on
the validation of SpO2 accuracy [29] and ISO 80601-2-61
[30]. The healthy volunteers underwent a desaturation proto-
col consisting of stepwise adjustments of the fraction of in-
spired oxygen (FiO2), targeting specific arterial oxygen satu-
ration (SaO2) level plateaus. A total of two “runs” per volun-
teer were performed. Every SpO2 plateau was held for about
30–60 s. Two blood samples were collected during the satu-
ration plateaus. Each run was then ended by several breaths of
100% O2 followed by room air while taking another sample
pair of blood samples. The number of plateaus per “run” was
adapted to the tolerance of the subjects to the desaturation
protocol. SpO2 was measured with several sensors on 5 dif-
ferent application sites; earlobe, forehead, cheek, upper arm,
and shoulder blade. SpO2 averaging time was set to 6 s. The
sensor temperature was set to 44 °C for most sensors. For
increasing statistical variety, several measurements were done
at 37 °C and 41 °C.
2.4 Statistical analysis
Descriptive statistics (mean/standard deviation or median/
range, depending on the distribution of the data) are given
for demographic data (age, gender, and BMI). Correlation
and Bland-Altman analyses were performed in order to deter-
mine Pearson’s correlation coefficient (r), bias (d), and stan-
dard deviation (SD). In concordance with the uniformity
of data presentation that follows from guideline ISO
80601-2-61:2011, the accuracy root mean square error
(Arms) was calculated with limits of agreement that did
no t take repea ted measurements in to account
( Arms ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
∑
n
i¼1
y^i−yið Þ2
n
r
¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
d2 þ SD2
p
Arms ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
∑
n
i¼1
y^i−yið Þ2
n
r
¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
d2 þ SD2
p
). In this formula, y^i is the SpO2 value for iter-
ation number i, yi is the measured SaO2 value for the iteration
number i, n is the number of samples, and d is the bias. The
presented limits of agreement and the between-subject vari-
ance were calculated according to the methods of repeated
measurements as described by Bland and Altman [31].
3 Results
3.1 In vitro accuracy and drift of tcPO2 and tcPCO2
A total of 17 tcPCO2 and 18 tcPO2 data points were collected
with each of the 10 sensors. The number of available data
points and the correlation and Bland-Altman analyses of the
tcPO2 and tcPCO2 data compared with the gas O2 and CO2
partial pressures are shown in Fig. 2 and summarized in
Table 1. At oxygen tensions of over 700 mm Hg, agreement
of tcPO2 with the reference gas has decreased,
underestimating the pO2. Measurement drift over different
intervals shows a very small overall O2 drift (Table 2). Drift
of tcPCO2 is notably highest during the first hour, tcPO2 drift
is not equally affected.
3.2 Clinical use of tcPO2 and tcPCO2
Four examples of clinical events were selected from patient
files, are shown in Fig. 3, and include tcPO2 and tcPCO2 data,
as well as the SpO2 data obtained from standard of care pulse
oximetry. These examples contain both cardiorespiratory pa-
tient events and related clinical interventions. A tcPO2 re-
sponse time of approximately 2 min longer when compared
with SpO2 and a consequential dampening effect can be
observed.
3.3 Validation of SpO2 in healthy volunteers
A total of 12 healthy volunteers participated in the study. The
study demographics are shown in Table 3. At each step of the
test protocol, two blood samples were drawn, of which a
single-patient example is shown in Fig. 4(a). This resulted in
a total of 2244 SaO2-SpO2 data pairs. The median of all mea-
sured SaO2 values is 84.8% (IQR 76.1–93.4%, range 68.0–
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100.6%). The correlation plot of the SaO2 values with the
corresponding SpO2 measurements obtained with the
OxiVenT™ Sensor at all five measurement sites is shown in
Fig. 4(b). The accuracy and agreement analyses for the sepa-
rate measuring sites show the narrowest limits of agreement
when measuring at the forehead and cheek, with the highest
accuracy when measured at the forehead (Table 4).
4 Discussion
With these studies, we present data on the OxiVenT™
Sensor, the first combined tcPO2, tcPCO2, and SpO2
transcutaneous sensor incorporating an optical tcPO2 mea-
surement that is designed to eliminate measurement drift.
The in vitro results confirm a good tcPO2 accuracy and
negligible overall measurement drift. Decreased tcPO2 ac-
curacy and precision can be observed at very high oxygen
tensions, together with underestimation of PaO2. This is
most likely a consequence of the abundance of oxygen,
leading to a short fluorescence decay time in combination
with a high intensity. However, these supraphysiological
levels are not likely to be clinically relevant. TcPCO2
accuracy and drift are on par with previous sensor gener-
ations [32]. TcPCO2 drift is highest during the first hour
of measurement, possibly due to equilibration effects.
TcPO2 drift does not seem to be equally affected, provid-
ing a more consistently accurate measurement from onset.
Furthermore, SpO2 shows excellent correlation and agree-
ment with SaO2 values in adult volunteers, particularly
when measuring at the forehead or cheek. Although trans-
cutaneous blood gas measurements have retained their
place in the clinic after the introduction of pulse oximetry,
the technique has remained laborious [33–35]. When
measurements are considered to be in disagreement with
arterial values, they require training to be able to distin-
guish technical failure or measurement drift from patient
factors influencing the measurement. As a consequence,
transcutaneous monitoring is most often used when the
required dedicated attention is outweighed by the advan-
tages, such as in neonatal intensive care units or sleep
laboratories. The logical innovation in transcutaneous
blood gas monitoring is consequently the introduction of
drift-free measurement techniques, making transcutaneous
monitoring more accurate and easy to use. In the investi-
gated OxiVenT™ Sensor, an optical tcPO2 measurement
has been implemented for this purpose. The main patient-
related limitation of transcutaneous tcPO2 and tcPCO2
measurements is inaccuracy due to the influence of skin
thickness and microcirculatory impairment on the
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Fig. 2 Bland-Altman plots of the agreement of in vitro tcPO2 (a) and tcPCO2 (b) measurements with calibration gas mixtures. The accuracy, bias, and
limits of agreement (LoA) for each measurement are shown in Table 1.
Table 1 In vitro accuracy of
tcPO2 (0–100%) and tcPCO2 (0–
10%) measurements
Measurement Data points (n) Accuracy (mm Hg) Bias (mm Hg) Limits of agreement
(mm Hg)
r
Arms Lower Upper
tcPO2 180 3.0 (2.9) − 0.8 − 6.6 4.9 0.999
tcPCO2 170 1.1 (0.7) 0.8 − 0.7 2.2 0.999
Values measured with the OxiVenT™ Sensor and compared with calibration gas mixtures
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diffusion of blood gases [2, 18, 36]. TcPO2 accuracy is
known to suffer more from these influences than tcPCO2
accuracy due to the higher skin diffusion resistance to
oxygen [4], leading to wide limits of agreement in clinical
studies on tcPO2 [11, 37]. In addition, the traditional elec-
trochemical tcPO2 sensors contained Clark-type elec-
trodes, which consume oxygen as part of the measurement
[2, 6]. The implementation of an optical measurement
technique for tcPO2 therefore potentially has a greater
measurement technique–related impact on accuracy for
than it would have for tcPCO2. Clinical measurements
of tcPO2 and tcPCO2 in the Neonatal Intensive Care
Unit suggest good usability and response to clinical
events. The relatively long tcPO2 response time makes it
unsuitable for detecting apneic episodes and oxygenation
dips. In adults, the inability to measure tcPO2 values that
mirror PaO2 values limits the use in the adult population
to oxygen trend monitoring. However, the improved reli-
ability of the tcPO2 trend could clinically have a greater
impact than improved agreement with blood gas samples.
Data on the user preference of using either absolute values
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Fig. 3 Clinical examples of tcPO2 and tcPCO2 measured in preterm
neonates with the OxiVenT™ Sensor during relevant events,
supplemented with standard of care peripherally measured transmission
pulse oximetry. These examples show the following events: (a) Very
preterm neonate, born at a gestational age (GA) of 28 weeks and with a
birth weight (BW) of 1200 g. Drop in oxygen saturation to 56% SpO2 due
to retention of sputum, following by suctioning, accompanied by a
transient rise of tcPCO2 and decrease of tcPO2 down to 35 mm Hg. (b)
Extreme preterm neonate, GA 27 weeks, BW 800 g. Capillary blood
sampling at an extremity, leading to agitation and crying with a
consequential drop in oxygen saturation to 55% and tcPO2 to 16 mm
Hg. Noteworthy is the temporary drop in tcPCO2 due to crying,
followed by a rise due to a decline in respiratory effort. The patient’s
lungs were recruited due to clinical indications of bronchospasms. The
FiO2 was increased from 0.21 to 0.40 during this process. (c) Late preterm
neonate, GA 36 weeks, BW 2500 g. Short period of bradycardia which
was followed by a drop in oxygen saturation. As a clinical intervention,
the FiO2 was increased from 0.21 to 0.39 for 4 min, leading to a period of
hyperoxia up to 109 mm Hg that was undetected by pulse oximetry. (d)
Extreme preterm neonate, GA 24 weeks, BW 700 g. During nursing with
patient repositioning multiple episodes of bradycardia down to 50 heart
beats per minute, with drops in SpO2 down to 40% and slow recovery.
The decline in respiratory effort and slow recovery are reflected by the
clear and persistent elevation of CO2 levels
Table 3 Volunteers
characteristics No. of volunteers 12
Age (years) 25 (23–34)
Male/female 7/5
Skin type
- Dark 2
- Medium 5
- Light 5
Values are listed as median (range), where
applicable
Table 2 Data on drift of tcPO2 (24-h calibration interval) and tcPCO2
(12-h calibration interval)
Total drift during
calibration interval
(12 h/24 h) (%)
Drift during first
hour of calibration
interval (%/h)
Drift during last
hour of calibration
interval (%/h)
tcPO2 0.30 (0.63) 0.14 (0.28) 0.03 (0.21)
tcPCO2 − 2.53 (1.04) 0.49 (0.28) 0.18 (0.09)
Data is shown as mean (SD)
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or trends is however limited and specific for patient pop-
ulations. With the new OxiVenT™ Sensor, the potential of
optical techniques has been demonstrated. In clinical use,
this combined sensor will however still require frequent
calibration of the electrochemical tcPCO2 measurement,
negating the potential benefit on calibration strain for both
patients and personnel. Although this study provides use-
ful information on the technical performance of this new
combined sensor, clinical validation is needed to evaluate
its impact and limitations.
5 Conclusion
Our results show the successful integration of a new optical
oxygen measuring technique in a non-invasive, combined
tcPO2, tcPCO2, and SpO2 sensor. In vitro tcPCO2 measure-
ment performance is unchanged when compared with litera-
ture on previous sensor generations. Reflectance pulse oxim-
etry correlates well in a study on healthy volunteers. The new
optical tcPO2 measurement is virtually drift-free in vitro.
Despite showing good usability in clinical examples, the
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Fig. 4 (a) Single-patient example
of the controlled desaturation
protocol in which a stepwise
decrease in SpO2 is achieved by
controlled lowering of the FiO2.
Dots indicate the moments when
an arterial blood sample was
taken during a relative plateau
phase. (b) Correlation plot (r =
0.979) of SaO2 in % from all
arterial blood samples and SpO2
in % measured with the
OxiVenT™ Sensor at the moment
of blood sampling (n = 2244)
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clinical benefit needs to be proven. Additionally, clinical data
is needed to validate this sensor to arterial blood samples in
specific patient populations.
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